Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 16, Issue 10, p.3270-8 (1998)


Adult, Antibodies, Monoclonal, Antigens, CD20, Disease-Free Survival, Female, Follow-Up Studies, hematopoietic stem cell transplantation, Humans, Iodine Radioisotopes, Lymphoma, B-Cell, Male, Middle Aged, Radioimmunotherapy, Radiotherapy Dosage, RECURRENCE, Remission Induction


Radioimmunotherapy (RIT) is a promising treatment approach for B-cell lymphomas. This is our first opportunity to report long-term follow-up data and late toxicities in 29 patients treated with myeloablative doses of iodine-131-anti-CD20 antibody (anti-B1) and autologous stem-cell rescue.